LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma

Bioanalysis. 2018 Jun 1;10(11):851-862. doi: 10.4155/bio-2018-0003. Epub 2018 Jun 4.

Abstract

Aim: Compared with small molecules, LC-MS quantitation of larger biotherapeutic proteins such as antibodies and antibody-drug conjugates at the intact level presents many challenges in both LC and MS due to their higher molecular weight, bigger size, structural complexity and heterogeneity.

Results & conclusion: In this study, quantitation of an intact lysine-linked antibody-drug conjugate, trastuzumab emtansine is presented. Trastuzumab emtansine was extracted from rat plasma using bead-based immunoaffinity capture; after elution from the beads, it was directly analyzed on a LC-HRMS system. Quantitation using both extracted ion chromatogram and deconvoluted mass peaks was evaluated. A limit of quantitation was approximately 20 ng on column with a linear dynamic range from 5 to 100 μg/ml. In addition, the reproducibility and distribution of the drug-to-antibody ratio at different trastuzumab emtansine concentrations were discussed.

Keywords: ADCs; DAR; LC–HRMS; antibody–drug conjugates; drug-to-antibody ratio; intact quantitation; rat plasma; trastuzumab emtansine.

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Animals
  • Blood Chemical Analysis / methods*
  • Chromatography, Liquid / methods*
  • Immunoconjugates / blood*
  • Immunoconjugates / chemistry
  • Immunoconjugates / isolation & purification
  • Limit of Detection
  • Mass Spectrometry / methods*
  • Maytansine / analogs & derivatives*
  • Maytansine / blood
  • Maytansine / chemistry
  • Maytansine / isolation & purification
  • Rats
  • Trastuzumab / blood*
  • Trastuzumab / chemistry
  • Trastuzumab / isolation & purification

Substances

  • Immunoconjugates
  • Maytansine
  • Trastuzumab
  • Ado-Trastuzumab Emtansine